Brand-name vs compounded
Ro.co vs Novi: Brand-Name or Compounded? (2026)
Ro.co or Novi? Side-by-side 2026 pricing, medication and service comparison, extended to six and twelve-month totals.
Published · Pricing as published in our provider dataset, synced · Editorial scores 7.5 and 7.0 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
Put Ro.co and Novi side by side and the marketing reads almost identically. The programs underneath do not.
The dividing line is regulatory, not cosmetic: Ro.co works with product the FDA has reviewed and approved, while Novi runs on compounded medication prepared by a pharmacy rather than manufactured under an approved application. Everything else about the two — price, support, shipping — follows from that decision.
The comparison below starts from published pricing, converts it into annual cost, and then asks what the more expensive side is delivering for the difference. Undisclosed pricing is treated as a finding, not rounded into an estimate.
The short answer
- Lowest ongoing rate
- Ro.co — $39/mo against $133/mo, though only one of the two publishes enough to total a full year.
- FDA-approved medication
- Ro.co — FDA-approved Wegovy pill (oral GLP-1) and brand-name GLP-1 injectables — a finished product the FDA has reviewed, rather than a compounded preparation.
- Tirzepatide access
- Novi — Tirzepatide at $166/mo; the other side publishes semaglutide only.
- Easiest to pay for
- Ro.co — Neither publishes financing; both expect the full amount monthly.
Side-by-side comparison
The rows below are the ones that differ enough between these two to be worth your attention.
| Ro.co | Novi | |
|---|---|---|
| Advertised price | Get started online for $39 | Semaglutide from $133/mo, tirzepatide from $166/mo |
| Rate after promotions | $39/mo | $133/mo |
| Pricing structure | Promotional first month, then standard rate | Published rate per medication |
| Medication | FDA-approved Wegovy pill (oral GLP-1) and brand-name GLP-1 injectables | Compounded semaglutide and compounded tirzepatide |
| Payment options | Card only, no financing published | Card only, no financing published |
| Membership fee | None | None |
| How fast you start | Online consultation | Online intake |
| State coverage | Not published | Not published |
| Patient reviews | 40,215 | 50,124 |
| eRxDoctor score | 7.5/10 | 7.0/10 |
Ro.co vs Novi on total cost, not entry price
Comparing entry prices across these two would be actively misleading, because they escalate differently. These are the totals — six months and twelve — using each provider's own published rates and best available plan.
| Ro.co | Novi | |
|---|---|---|
| First month | $39 | $133 |
| Months 2 onward | Not published | $133/mo |
| 6-month total | Not computable | $798 |
| 12-month total | Not computable | $1,596 |
| Best published plan | No multi-month discount published | No multi-month discount published |
A like-for-like annual total is not available for Ro.co: ongoing medication pricing varies by plan and is set after the consultation. Treat any comparison that quotes one as an estimate someone else has made for you.
The regulatory difference, in plain terms
On Ro.co's side of the line sits FDA-approved Wegovy pill (oral GLP-1) and brand-name GLP-1 injectables — product manufactured under an approved application, with the batch-to-batch consistency that approval requires.
Novi supplies compounded semaglutide and compounded tirzepatide — compounded medication prepared by a pharmacy rather than manufactured under an approved application. That is what makes $133/mo possible in the first place, and it is also why the oversight is not the same.
This is the decision to make deliberately rather than by price. If the regulatory status of what you are injecting weekly matters to you, that settles it toward Ro.co; if cost is the barrier that has kept you from treating at all, Novi exists for a reason.
Ro.co: what you are buying
The pitch is the only mainstream platform here offering the FDA-approved Wegovy pill, so no injections at all. Get Started Online for Just $39
You start with online consultation; medication arrives via home delivery. The price behaves as promotional first month, then standard rate.
Ongoing care is established full-service platform with clinician oversight, and the medication list runs to FDA-approved Wegovy pill (oral GLP-1) and brand-name GLP-1 injectables.
Ro.co pros
- No hidden fees; pricing disclosed before you complete your consultation
- Only mainstream platform offering the FDA-approved Wegovy pill, oral GLP-1, no injections
- Get started online for just $39
- FDA-approved finished medication, not compounded
Ro.co cons
- Ongoing medication pricing varies and can be high depending on the plan
- Branded and FDA-approved medications cost significantly more than compounded alternatives
- Less price-competitive than compounded-only platforms for budget-driven patients
Against Novi specifically, the trade you are making: an FDA-approved finished medication costs multiples of a compounded vial.
A closer look at Novi
$200 OFF - GLP-1 for $133 Today
The process is online intake, then free 2-day shipping with every order. On money, expect published rate per medication — published upfront.
Support: no long-term contract, cancel anytime. The medications on offer are compounded semaglutide and compounded tirzepatide.
Novi pros
- Competitive pricing: semaglutide from $133/month and tirzepatide from $166/month
- Largest patient base on this list, 50,000+ patients, signaling operational maturity
- Both compounded semaglutide and tirzepatide available
- Free 2-day shipping included with every order
Novi cons
- Compounded medication only, no branded Ozempic, Wegovy, or Zepbound
- Tirzepatide ($166) costs more than the semaglutide entry rate
- No published outcome or weight loss guarantee
The cost of choosing this over Ro.co: the $133 rate depends on a $200-off promotion and there is no outcome guarantee.
Who each program is actually built for
Choose Ro.co if:
- you want to start on their timeline: online consultation
- delivery works the way you want it to: home delivery
- the monthly rate is the constraint — $39/mo against $133/mo
- you want an FDA-approved finished medication rather than a compounded preparation
Choose Novi if:
- you want tirzepatide available without changing provider later
- you want the full price in front of you before completing an intake
- you would get real value from the narrowest gap here between semaglutide and tirzepatide pricing, at $133 and $166
- the level of clinical contact suits you: no long-term contract, cancel anytime
The trade-offs, stated plainly
On price. The monthly gap is 3.4x in Ro.co's favor. Whether that is a saving or a false economy turns on one thing: an FDA-approved finished medication costs multiples of a compounded vial.
On commitment. Neither publishes a multi-month discount, so both are month-to-month decisions and neither asks you to prepay for a response you have not had yet. Neither publishes financing options, so plan for the full amount each month.
On clinical contact. Established full-service platform with clinician oversight at Ro.co; no long-term contract, cancel anytime at Novi. Neither is a substitute for in-person care if you have complicating conditions, and both bill you directly rather than your insurer.
On medication. Ro.co covers FDA-approved Wegovy pill (oral GLP-1) and brand-name GLP-1 injectables; Novi covers compounded semaglutide and compounded tirzepatide. Only Novi publishes a tirzepatide route, which matters if semaglutide underdelivers.
Evidence and regulatory status
Before either program's marketing claims, the underlying evidence — which belongs to the medication, not the platform.
The NIH position is that weight-management medication works alongside changes in eating and activity, not instead of them, per NIH, NIDDK.
Cardiovascular benefit has been demonstrated for semaglutide in a specific population: adults with overweight or obesity and existing cardiovascular disease but no diabetes, per NEJM, SELECT.
Read alongside the pricing above, that is the case for treating the medication decision as clinical and the provider decision as commercial. They are not the same choice.
Ro.co vs Novi: common questions
What happens when Ro.co's promotional price ends?
Ongoing medication pricing varies by plan and is set after the consultation. Ask for it before the first charge, since it governs almost the entire cost of a year of treatment.
Which is cheaper to start, Ro.co or Novi?
Ro.co, at $39 against $133. Note that the cheapest first month and the cheapest year are often different providers here — check the 12-month row of the cost table before deciding on the entry price.
Which has more patient reviews, Ro.co or Novi?
Novi, with 50,124 against 40,215. Ratings across this market cluster tightly, so volume is the more useful signal: it indicates how much operational load the platform has already absorbed, not how good the medication is.
Are Ro.co and Novi legitimate?
Both are licensed telehealth platforms that route a prescription through a clinician review before anything is dispensed; neither sells medication without one. Ro.co operates on promotional first month, then standard rate with pricing partly published, Novi on published rate per medication, published upfront. The meaningful due diligence is on the medication category and the terms, not on whether the platforms are real.
Is Ro.co or Novi better for a first GLP-1 prescription?
If this is your first GLP-1, the question is who answers when nausea arrives on day nine. Ro.co publishes established full-service platform with clinician oversight, which is the more useful thing to buy at the start.
What happens if I stop taking the medication?
Weight regain is the documented pattern, and it is not specific to either platform. Trial extension data has recorded participants regaining most of the weight they lost within a year of stopping semaglutide. Both Ro.co and Novi price on a monthly basis, so treat the twelve-month figure as the realistic commitment rather than a first-month experiment.
Does Ro.co or Novi offer tirzepatide?
Novi does, at $166/mo. Ro.co publishes FDA-approved Wegovy pill (oral GLP-1) and brand-name GLP-1 injectables only, so moving to tirzepatide would mean moving provider — a new intake, a new price, and the loss of any rate you had locked in.
The verdict
Ro.co is the cheaper of the two to run at $39/mo, but a full-year total is only computable for one side of this comparison, so treat that as a directional finding rather than a settled one.
Novi's case is the narrowest gap here between semaglutide and tirzepatide pricing, at $133 and $166; its cost: the $133 rate depends on a $200-off promotion and there is no outcome guarantee.
Neither choice is irreversible. Start with the program whose weaknesses you can tolerate, and reassess at month three when you know how you respond to the medication.
Keep comparing
- Ro.co vs MaximusBrand-name vs compounded
- Ro.co vs He & She MDBrand-name vs compounded
- Novi vs Mochi HealthTirzepatide access
- LIV Body vs NoviBudget vs premium
- Hers vs RefillsBrand-name vs compounded
- Hers vs MeasuredBrand-name vs compounded
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Ro.co or Novi, and does not sell treatment. Read our ranking methodology.